



Subject: Lupron (Leuprolide) and other Injectable or Implantable GnRH Analogs*

Effective Date: May 1, 1999

Department(s) Utilization Management

Policy: Leuprolide (Lupron) or other injectable or implantable GnRH analogs are reimbursable for medically necessary indications delineated in this policy, under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to limit reimbursement for a class of drugs to medically necessary indications.

Procedure:

1. Reimbursable indications for Leuprolide or other GnRH analogs include, but are not limited to, the following:

- Management of infertility (**ICD-9 628.0 – 628.9; ICD-10 N97.0-N97.9**) leuprolide, cetorelix, ganirelix
- Prostatic cancer (**ICD-9 185; ICD-10 C61**) leuprolide, histrelin(Vantas), triptorelin, degarelix
- Endometriosis (**ICD-9 617.0 – 617.9; ICD-10 N80.0-N80.9**) goserelin, leuprolide, triptorelin
- Uterine leiomyomata (**ICD-9 218.0 – 218.9; ICD-10 D25.0-D25.9**) leuprolide, triptorelin
- Polycystic ovary syndrome (**ICD-9 256.4; ICD-10 E28.2**)
- Central precocious puberty (**ICD-9 259.1; ICD-10 E30.1**) leuprolide, histrelin(Supprelin LA), triptorelin
- Dysfunctional uterine bleeding (**ICD-9 626.8; ICD-10 N89.7, N92.5, N93.8**) goserelin
- Premenopausal breast cancer (**ICD-9 174-174.5; ICD-10 C50-C50.31**) TNM stages pT1, pT2, or pT3 and pN0 or pN1mi, that is ER/PR positive, when used in combination with tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy (goserelin and leuprolide)

- Metastatic breast cancer (ICD-9 174.9; ICD-10 C50.911-C50.919) leuprolide, goserelin
 - Relapsed ovarian granulosa cell tumors (ICD-9 183.2; ICD-10 C56.1-C56.9) Leuprolide
 - Recurrent ovarian cancer, fallopian and primary peritoneal cancer (ICD-9 183.0, 183.2, 158.8-158.9; ICD-10 C56.1-C56.9, C57.00-C57.02, C45.1, C48.1-C48.8) Leuprolide
2. All requests for Leuprolide and other GnRH analogs must undergo medical review except when they are prescribed for management of infertility.
 3. Preparations of Leuprolide include, but are not limited to, the following:

Eligard; Lupron Depot-Ped; Lupron Depot; Lupron;
 4. Other GnRH analogs include, but are not limited to, the following (brand names in parentheses):

Cetrorelix (Cetrotide); Ganirelix (Follistim/Antagon; Goserelin (Zoladex); Histrelin (Supprelin, Vantas); Triptorelin (Trelstar Depot), degarelix (Firmagon)

References

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Ovarian Cancer Including Fallopian Tube cancer and Primary Peritoneal cancer Version 2.2015. accessed online 05/02/16 at nccn.org

National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer Version 2.2016. accessed online 05/02/16 at nccn.org

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 2.2016 accessed online 6/23/16 at nccn.org.

Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2015;126(1):187-95(Jul)

Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). *Reprod Biol Endocrinol.* 2012;10:26(Apr)

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Ovarian Cancer Including Fallopian Tube cancer and Primary Peritoneal cancer Version 1.2013. accessed online 01/09/13 at nccn.org

Chen I, Motan T, Kiddoo D. Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials. *2011 J Minim Invasive Gynecol*;18(3):303-9(May-Jun)

Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. *2012 Int J Urol*;19(7):594-601(Jul)

Bhatia K, Doonan Y, Giannakou A, *et al.* A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium. *BJOG* 2008;115(10):1214-1224 (Sep)

Shahani S, Braga-Basaria M, Basaria S. Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis. *J Clin Endocrinol Metab* 2008;93(6):2042-2049 (Jun)

Pasquino AM, Pucarelli I, Accardo F, *et al.* Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, bone Mineral Content, and Reproductive Function. *J Clin Endocrinol Metab* 2008;93(1):190-195 (Jan)

Eugster EA, Clarke W, Kletter GB, *et al.* Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial. *J Clin Endocrinol Metab* 2007;92(5):1697-1704 (May)

Garibaldi L. Disorders of Pubertal Development. Ch 563 in Kliegman RM, Behrman RE, Jenson HB, *et al.* *Nelson Textbook of Pediatrics*. 18th ed. Philadelphia. Saunders Elsevier. 2007

Higano C. Androgen Deprivation Therapy: Monitoring and Managing the Complications. *Hematol/Oncol Clin N Amer* 2006;20(4):909-923 (Aug)

----Leuprolide: Drug Information. *UpToDate OnLine* 13.3 (2006) www.uptodate.com

Buggs D, Rosenfield RL. Polycystic ovary syndrome in adolescence. *Endocrinol Metab Clin N Amer* 2005;34(3):677-705 (Sep)

Mahutte NG, Arici A. Medical management of endometriosis-associated pain. *Obstet Gynecol Clin N Amer* 2003;30(1):133-150 (Mar)

Drafted By/Date: L. Vogel, MD 03/99
Approved By/Date: QM Committee 4/27/99
Revised By/Date: B. Fisher, MD 02/22/06
Approved By/Date: QM Committee 03/28/06
Revised By/Date: B. Fisher, MD, E. Minaya, MD 10/30/08
Approved By/Date: QM Committee 12/09/08
Reviewed w/o Revision By/Date: MMcNeil MD 11/29/10
Approved By/Date: QMC, 01/25/11
Revised By/Date: MMcNeil, MD 01/09/13
Approved By/Date: QM Committee 1/22/13
Revised By/Date: M McNeil, MD 06/23/16
Approved By/Date: QM Committee 08/23/16

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.

